Last reviewed · How we verify
Epiduo/Tactuo
Epiduo/Tactuo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria.
Epiduo/Tactuo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria. Used for Acne vulgaris.
At a glance
| Generic name | Epiduo/Tactuo |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Retinoid + peroxide combination |
| Target | Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize follicular keratinization and reduce comedone formation. Benzoyl peroxide provides antimicrobial activity against Cutibacterium acnes (formerly Propionibacterium acnes) and has mild keratolytic effects. Together, they address multiple pathogenic factors in acne development.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Scaling/peeling
- Dryness
- Irritation
- Photosensitivity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epiduo/Tactuo CI brief — competitive landscape report
- Epiduo/Tactuo updates RSS · CI watch RSS
- Galderma R&D portfolio CI